InnoCare Pharma 9969.HK · HKD

Its shares trade on HKEX under the ticker 9969.HK. It has been listed since 23 March 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.30bn and net income of CN¥625.8m. At that date it held total assets of CN¥10.83bn and shareholders' equity of CN¥7.73bn.

InnoCare Pharma Ltd. is a clinical-stage biopharmaceutical company. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-03-23. The firm discovers, develops and commercializes potentially best-in-class and first-in-class drugs for the treatment of cancer and autoimmune diseases. The firm builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Jisong CuiExecutive Chairman of the Board, Chief Executive Officer, since 2015CN¥29.4m
• Mr. Shaojing TongChief Financial Officer
• Mr. Nan GaoChief Operation Officer
• Dr. Xiangyang ChenChief Technology Officer
• Ms. Junsu WangGeneral Manager
• Dr. Renbin ZhaoExecutive Director, since 2015CN¥2.0m
• Mr. Xiaodong JinChief Commercial Officer
• Dr. Xiang-Yang ZhangChief Medical Officer
• Ms. Angel Pui Shan LeeCompany Secretary
• Mr. Ming JinNon-Executive Director
• Dr. Yigong ShiNon-Executive Director
• Mr. Ronggang XieNon-Executive Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.